PaperQA2 now natively supports querying clinical trials in addition to any documents supplied by the user. It uses a new tool, the aptly named clinical_trials_search tool. Users don't have to provide any clinical trials to the tool itself, it uses the clinicaltrials.gov API to retrieve them on the fly. As of January 2025, the tool is not enabled by default, but it's easy to configure. Here's an example where we query only clinical trials, without using any documents:
from paperqa import Settings, agent_query
answer_response = await agent_query(
query="What drugs have been found to effectively treat Ulcerative Colitis?",
settings=Settings.from_name("search_only_clinical_trials"),
)
print(answer_response.session.answer)Several drugs have been found to effectively treat Ulcerative Colitis (UC),
targeting different mechanisms of the disease.
Golimumab, a tumor necrosis factor (TNF) inhibitor marketed as Simponi®, has demonstrated efficacy
in treating moderate-to-severe UC. Administered subcutaneously, it was shown to maintain clinical
response through Week 54 in patients, as assessed by the Partial Mayo Score (NCT02092285).
Mesalazine, an anti-inflammatory drug, is commonly used for UC treatment. In a study comparing
mesalazine enemas to faecal microbiota transplantation (FMT) for left-sided UC,
mesalazine enemas (4g daily) were effective in inducing clinical remission (Mayo score ≤ 2) (NCT03104036).
Antibiotics have also shown potential in UC management. A combination of doxycycline,
amoxicillin, and metronidazole induced remission in 60-70% of patients with moderate-to-severe
UC in prior studies. These antibiotics are thought to alter gut microbiota, reducing pathobionts
and promoting beneficial bacteria (NCT02217722, NCT03986996).
Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, is being investigated for mild-to-moderate UC.
Preliminary findings suggest it may improve disease severity and biochemical markers when
added to conventional treatments (NCT05684484).
These treatments highlight diverse therapeutic approaches, including immunosuppression,
microbiota modulation, and anti-inflammatory mechanisms.You can see the in-line citations for each clinical trial used as a response for each query. If you'd like to see more data on the specific contexts that were used to answer the query:
print(answer_response.session.contexts)[Context(context='The excerpt mentions that a search on ClinicalTrials.gov for clinical trials related to drugs
treating Ulcerative Colitis yielded 689 trials. However, it does not provide specific information about which
drugs have been found effective for treating Ulcerative Colitis.', text=Text(text='', name=...Using Settings.from_name('search_only_clinical_trials') is a shortcut, but note that you can easily add clinical_trial_search into any custom Settings by just explicitly naming it as a tool:
from pathlib import Path
from paperqa import Settings, agent_query, AgentSetting
from paperqa.agents.tools import DEFAULT_TOOL_NAMES
# you can start with the default list of PaperQA tools
print(DEFAULT_TOOL_NAMES)
# >>> ['paper_search', 'gather_evidence', 'gen_answer', 'reset', 'complete'],
# we can start with a directory with a potentially useful paper in it
print(list(Path("my_papers").iterdir()))
# now let's query using standard tools + clinical_trials
answer_response = await agent_query(
query="What drugs have been found to effectively treat Ulcerative Colitis?",
settings=Settings(
paper_directory="my_papers",
agent={"tool_names": DEFAULT_TOOL_NAMES + ["clinical_trials_search"]},
),
)
# let's check out the formatted answer (with references included)
print(answer_response.session.formatted_answer)Question: What drugs have been found to effectively treat Ulcerative Colitis?
Several drugs have been found effective in treating Ulcerative Colitis (UC), with treatment
strategies varying based on disease severity and extent. For mild-to-moderate UC, 5-aminosalicylic
acid (5-ASA) is the first-line therapy. Topical 5-ASA, such as mesalazine suppositories (1 g/day),
is effective for proctitis or distal colitis, inducing remission in 31-80% of patients. Oral mesalazine
at higher doses (e.g., 4.8 g/day) can accelerate clinical improvement in more extensive disease
(meier2011currenttreatmentof pages 1-2; meier2011currenttreatmentof pages 3-4).
For moderate-to-severe cases, corticosteroids are commonly used. Oral steroids like prednisolone
(40-60 mg/day) or intravenous steroids such as methylprednisolone (60 mg/day) and hydrocortisone
(400 mg/day) are standard for inducing remission (meier2011currenttreatmentof pages 3-4). Tumor
necrosis factor (TNF)-α blockers, such as infliximab, are effective for steroid-refractory cases
(meier2011currenttreatmentof pages 2-3; meier2011currenttreatmentof pages 3-4).
Immunosuppressive agents, including azathioprine and 6-mercaptopurine, are used for maintenance
therapy in steroid-dependent or refractory cases (meier2011currenttreatmentof pages 2-3;
meier2011currenttreatmentof pages 3-4). Antibiotics, such as combinations of penicillin,
tetracycline, and metronidazole, have shown promise in altering the microbiota and inducing
remission in some patients, though their efficacy varies (NCT02217722).
References
1. (meier2011currenttreatmentof pages 2-3): Johannes Meier and Andreas Sturm. Current treatment
of ulcerative colitis. World journal of gastroenterology, 17 27:3204-12, 2011.
URL: https://doi.org/10.3748/wjg.v17.i27.3204, doi:10.3748/wjg.v17.i27.3204.
2. (meier2011currenttreatmentof pages 3-4): Johannes Meier and Andreas Sturm. Current treatment
of ulcerative colitis. World journal of gastroenterology, 17 27:3204-12, 2011. URL:
https://doi.org/10.3748/wjg.v17.i27.3204, doi:10.3748/wjg.v17.i27.3204.
3. (NCT02217722): Prof. Arie Levine. Use of the Ulcerative Colitis Diet for Induction of
Remission. Prof. Arie Levine. 2014. ClinicalTrials.gov Identifier: NCT02217722
4. (meier2011currenttreatmentof pages 1-2): Johannes Meier and Andreas Sturm. Current
treatment of ulcerative colitis. World journal of gastroenterology, 17 27:3204-12, 2011.
URL: https://doi.org/10.3748/wjg.v17.i27.3204, doi:10.3748/wjg.v17.i27.3204.We now see both papers and clinical trials cited in our response. For convenience, we have a Settings.from_name that works as well:
from paperqa import Settings, agent_query
answer_response = await agent_query(
query="What drugs have been found to effectively treat Ulcerative Colitis?",
settings=Settings.from_name("clinical_trials"),
)And, this works with the pqa cli as well:
>>> pqa --settings 'search_only_clinical_trials' ask 'what is Ibuprofen effective at treating?'...
[13:29:50] Completing 'what is Ibuprofen effective at treating?' as 'certain'.
Answer: Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) effective
in treating various conditions, including pain, inflammation, and fever.
It is widely used for tension-type
headaches, with studies showing that ibuprofen sodium provides significant
pain relief and reduces pain intensity compared to standard ibuprofen and placebo
over a 3-hour period (NCT01362491).
Intravenous ibuprofen is effective in managing postoperative pain, particularly
in orthopedic surgeries, and helps control the inflammatory process. When combined
with opioids, it reduces opioid
consumption and associated side effects, making it a key component of
multimodal analgesia (NCT05401916, NCT01773005).
Ibuprofen is also effective in pediatric populations as a first-line
anti-inflammatory and antipyretic agent due to its relatively
low adverse effects compared to other NSAIDs (NCT01478022).
Additionally, it has been studied for its potential use in managing
chronic periodontitis through subgingival irrigation with a 2% ibuprofen
mouthwash, which reduces periodontal pocket depth and
bleeding on probing, improving periodontal health (NCT02538237).
These findings highlight ibuprofen's versatility in treating pain, inflammation,
fever, and specific conditions like tension headaches, postoperative pain, and periodontal diseases.